Literature DB >> 29494736

Association of Continued Preoperative Aspirin Use and Bleeding Complications in Patients Undergoing Thyroid Surgery.

Blake S Raggio1, Blair M Barton1, Emad Kandil1, Paul L Friedlander1.   

Abstract

IMPORTANCE: No evidence exists to direct the management of preoperative aspirin (acetylsalicylic acid) use in patients undergoing thyroid surgery. Nevertheless, a considerable number of patients interrupt receiving aspirin therapy during the preoperative period to minimize bleeding complications despite the increased risk of experiencing major adverse cardiac events.
OBJECTIVE: To determine whether aspirin therapy continued preoperatively increases bleeding complications in patients undergoing thyroid surgery. DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of a consecutive sample of 570 patients, aged 18 to 100 years, who underwent thyroid surgery for benign and malignant disease from January 1, 2010, to December 31, 2015, by a single surgeon at a tertiary referral hospital center in New Orleans, Louisiana. EXPOSURES: Patients receiving aspirin therapy and patients not receiving aspirin therapy (aspirin naive) preoperatively. MAIN OUTCOMES AND MEASURES: Comparison of estimated blood loss, substantial blood loss, operative hematoma, nonoperative hematoma, and recurrent laryngeal nerve injury.
RESULTS: Of 570 patients who underwent thyroid surgery, 106 (18.6%) were performed in patients receiving aspirin; of these, 23 (21.7%) were men and 105 (99.1%) were older than 45 years. Those receiving aspirin therapy displayed a 14.4-year difference in age (95% CI, 11.6-17.1). The aspirin group displayed a 20.3% absolute increase (95% CI, 9.3-30.7) in African American patients. Aspirin therapy was not associated with a statistically significant or clinically meaningful increase in intraoperative blood loss (2.5 mL; 95% CI, -0.4 to 5.3). Aspirin therapy was associated with a statistically significant increase in total hematoma formation (3.3%; 95% CI, 0.4-9.0), but the results were inconclusive. Aspirin therapy was not associated with a statistically significant increase in recurrent laryngeal nerve injury (2.6%; 95% CI, -1.1 to 8.6), but the results were inconclusive. CONCLUSIONS AND RELEVANCE: These results suggest that aspirin therapy can be maintained prior to thyroid surgery without increased intraoperative bleeding. Further research with a larger sample size and more outcome events are required to make definitive conclusions regarding the association between aspirin use and complications, including hematoma and recurrent laryngeal nerve injury.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29494736      PMCID: PMC5876801          DOI: 10.1001/jamaoto.2017.3262

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  45 in total

1.  Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery.

Authors:  L Broad; T Lee; M Conroy; S Bolsin; N Orford; A Black; G Birdsey
Journal:  Br J Anaesth       Date:  2006-11-22       Impact factor: 9.166

2.  Risk factors target in patients with post-thyroidectomy bleeding.

Authors:  Endong Chen; Yefeng Cai; Quan Li; Pu Cheng; Chunjue Ni; Langping Jin; Qianqing Ji; Xiaohua Zhang; Chun Jin
Journal:  Int J Clin Exp Med       Date:  2014-07-15

Review 3.  Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.

Authors:  W Burger; J-M Chemnitius; G D Kneissl; G Rücker
Journal:  J Intern Med       Date:  2005-05       Impact factor: 8.989

Review 4.  Perioperative antiplatelet therapy.

Authors:  Pierre Guy Chassot; Carlo Marcucci; Alain Delabays; Donat R Spahn
Journal:  Am Fam Physician       Date:  2010-12-15       Impact factor: 3.292

5.  Lack of evidence for increased postoperative bleeding risk for dental osteotomy with continued aspirin therapy.

Authors:  Henning Hanken; Ferdinand Tieck; Lan Kluwe; Ralf Smeets; Max Heiland; Clarissa Precht; Marc Eichhorn; Wolfgang Eichhorn
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2014-09-16

Review 6.  Antiplatelet agents and perioperative bleeding.

Authors:  Thomas Lecompte; Jean-François Hardy
Journal:  Can J Anaesth       Date:  2006-06       Impact factor: 5.063

7.  Causes for early reintervention after thyroidectomy.

Authors:  Luis Mauricio Hurtado-López; Felipe Rafael Zaldivar-Ramirez; Erich Basurto Kuba; Abraham Pulido Cejudo; Jose Humberto Garza Flores; Oscar Muńoz Solis; Carlos Campos Castillo
Journal:  Med Sci Monit       Date:  2002-04

8.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

Review 9.  Continuation of medically necessary aspirin and warfarin during cutaneous surgery.

Authors:  Clark C Otley
Journal:  Mayo Clin Proc       Date:  2003-11       Impact factor: 7.616

Review 10.  The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors.

Authors:  Axel Schlitt; Csilla Jámbor; Michael Spannagl; Wiebke Gogarten; Tom Schilling; Bernhard Zwissler
Journal:  Dtsch Arztebl Int       Date:  2013-08-05       Impact factor: 5.594

View more
  2 in total

1.  Long-term assessment of aspirin desensitization shows successful bridging with non-aspirin nonsteroidal anti-inflammatory drugs for procedures.

Authors:  Toan Do; Ethan Canty; Puneet Bajaj; Faoud Ishmael; Timothy Craig
Journal:  Allergy Asthma Proc       Date:  2019-09-01       Impact factor: 2.587

2.  A cervical compartment syndrome impairs cerebral circulation in post-thyroidectomy hemorrhage: data from an animal model.

Authors:  Ulrich Wirth; Josefine Schardey; Magdalena Bonleitner; Desiree Weber; Thomas von Ahnen; Roland Ladurner; Joachim Andrassy; Jens Werner; Hans Martin Schardey; Stefan Schopf
Journal:  Gland Surg       Date:  2022-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.